Roth Capital Starts Global Blood Therapeutics (GBT) at Buy
Tweet
Share
E-mail
Get Alerts GBT Hot Sheet
Price: $68.49 --0%
Rating Summary:
12 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
12 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Roth Capital analyst Elemer Piros initiates coverage on Global Blood Therapeutics (NASDAQ: GBT) with a Buy rating and a price target of $129.00.
For an analyst ratings summary and ratings history on Global Blood Therapeutics click here. For more ratings news on Global Blood Therapeutics click here.
Shares of Global Blood Therapeutics closed at $74.49 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Wedbush Starts Immunic Inc. (IMUX) at Outperform
- Truist Securities Reinstates Pacira Pharmaceuticals (PCRX) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
